Endpoints News
Bayer's ready for more M&A Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
12 May, 2026
A Better Way to AAV.
Helping you scale your gene therapy with greater efficiency.
sponsored by Forge Biologics
presented by Parexel Biotech
Mov­ing be­yond sci­ence to ac­cess: Solv­ing the ac­cess im­per­a­tive
top stories
1. Five burning questions for Isomorphic after its mammoth $2B+ raise
2. Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
3. Pfizer and Arvinas give disappointing breast cancer drug to Rigel
4.
news briefing
Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
5. Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
6. Flagship startup says it has solved non-viral gene therapy in monkeys, but details remain murky
7. Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
8. Exclusive: Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
9. Optum Rx unveils pharmacy model with clear fees, building on transparency push
more stories
• 
Alex Hoffman
.

Isomorphic Labs, which aims to use AI to speed drug development, raised over $2 billion in its Series B. Andrew Dunn has followed the company closely and asked its president five burning questions about the deal.
.
Alex Hoffman
Senior Copy Editor, Endpoints News
Demis Hassabis, Isomorphic Labs CEO (Chris Jung/NurPhoto via AP Images)
1
by Andrew Dunn

Iso­mor­phic Labs said Tues­day it had closed a $2.1 bil­lion Se­ries B round, ce­ment­ing its bell­wether role in us­ing AI for drug dis­cov­ery.

For pri­vate­ly...

Read full story
Bill Anderson, Bayer CEO (Sean Gallup/Getty Images)
2
by Ayisha Sharma

Bay­er is back on the mar­ket for drug ac­qui­si­tions af­ter a half-decade on the side­lines, ac­cord­ing to CEO Bill An­der­son.

“We’re go­ing to be care­ful...

Read full story
3
by Lei Lei Wu

Pfiz­er has turned $1 bil­lion in­to $35 mil­lion.

The New York-based phar­ma com­pa­ny and its part­ner Arv­inas are sell­ing rights to their re­cent­ly ap­proved breast...

Read full story
US Pharma and Biotech Summit - May 14, 2026
Policy shifts, regulatory unknowns, and a dealmaking environment that won’t sit still — US biopharma is navigating serious uncertainty. Join FT Live and Endpoints News for the conversations that will define what comes next.
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus, news from Vista­gen, En­ter­prise Ther­a­peu­tics, Cere­vance and Me­men­to Med­i­cines.

😴 Alk­er­mes’ nar­colep­sy drug suc­ceeds in Phase 3 study: The com­pa­ny’s drug Lum­ryz, ap­proved in...

Read full story
5